Nkarta Q2 net loss $25M; cash $426.7M; plans Ntrust-2 trial by year-end

Nkarta, Inc.

2024-Q2 EPS reported -$0.88

Net loss of $25.0M ($0.34 per share) for Q2 2024; R&D expenses $23.1M, G&A $7.6M.
Cash, equivalents and investments of $426.7M at June 30, 2024; expected to fund operations into late 2027.
FDA clearance received for second IND for NKX019 in autoimmune disease; Ntrust-2 enrollment expected by year-end 2024.
Preliminary data from Ntrust-1 and Ntrust-2 planned for 2025; IST in SLE/LN initiated at Columbia University.
Nadir Mahmood joined as President; David Shook promoted to CMO, Head of R&D in July 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.